Lista de obras - Aline Renneville - Dominio Público Uruguay

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

artículo científico publicado en 2019

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

artículo científico

Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): evolution on hypomethylating agent therapy

artículo científico publicado en 2011

Acute myeloid leukemia with translocation t(3;5): new molecular insights.

artículo científico publicado en 2013

B7-H3 protein expression in acute myeloid leukemia

artículo científico publicado en 2015

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

artículo científico publicado en 2013

Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia

artículo científico publicado en 2008

Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial

artículo científico publicado en 2014

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.

artículo científico publicado en 2018

Clonal architecture of chronic myelomonocytic leukemias

artículo científico publicado en 2013

Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes

artículo científico publicado en 2015

Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study

artículo científico publicado en 2011

Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

artículo científico publicado en 2011

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

artículo científico publicado en 2015

Exome analysis of treatment-related AML after APL suggests secondary evolution

scientific article published on 22 November 2018

Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.

artículo científico publicado en 2014

Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia

artículo científico publicado en 2018

Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia

artículo científico publicado en 2010

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia.

artículo científico publicado en 2013

Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia

artículo científico publicado en 2015

Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia

scholarly article by Ashfaq Ali et al published 26 February 2018 in Leukemia

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.

artículo científico publicado en 2009

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

artículo científico publicado en 2015

Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia.

artículo científico publicado en 2014

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

artículo científico publicado en 2010

Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis.

artículo científico publicado en 2015

Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis

scientific article published on 04 August 2012

Linezolid induces ring sideroblasts

artículo científico publicado en 2013

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

artículo científico publicado en 2014

MYD88 L265P mutation in Waldenstrom macroglobulinemia.

artículo científico publicado en 2013

MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations.

artículo científico publicado en 2012

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.

artículo científico publicado en 2011

Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA

artículo científico publicado en 2014

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

artículo científico publicado en 2011

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

artículo científico publicado en 2012

Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis.

artículo científico publicado en 2017

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia

artículo científico publicado en 2015

Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial

artículo científico publicado en 2012

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

artículo científico publicado en 2016

Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype

artículo científico publicado en 2005

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

artículo científico publicado en 2018

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

artículo científico publicado en 2013

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

artículo científico publicado en 2014

Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group.

artículo científico publicado en 2015

Quantification of JAK2V617F mutation by next-generation sequencing technology.

artículo científico publicado en 2013

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

artículo científico publicado en 2013

Slow relapse in acute myeloid leukemia with inv(16) or t(16;16).

artículo científico publicado en 2009

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older

artículo científico publicado en 2012

TP53 mutation and its prognostic significance in Waldenstrom's Macroglobulinemia

artículo científico publicado en 2017

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants

artículo científico publicado en 2020

Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association

artículo científico publicado en 2009

Lista de obras de Aline Renneville

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): evolution on hypomethylating agent therapy

Acute myeloid leukemia with translocation t(3;5): new molecular insights.

B7-H3 protein expression in acute myeloid leukemia

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia

Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.

Clonal architecture of chronic myelomonocytic leukemias

Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes

Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study

Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

Exome analysis of treatment-related AML after APL suggests secondary evolution

Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.

Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia

Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia.

Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia

Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia.

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis.

Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis

Linezolid induces ring sideroblasts

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

MYD88 L265P mutation in Waldenstrom macroglobulinemia.

MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations.

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.

Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis.

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia

Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group.

Quantification of JAK2V617F mutation by next-generation sequencing technology.

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Slow relapse in acute myeloid leukemia with inv(16) or t(16;16).

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older

TP53 mutation and its prognostic significance in Waldenstrom's Macroglobulinemia

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants

Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association